What are the differences between n‑butyl cyanoacrylate and 2‑octyl cyanoacrylate adhesives, and is either of them the same as Dermabond (2‑octyl cyanoacrylate), given prior skin reactions to Dermabond?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Dermabond is 2-octyl cyanoacrylate, and if you experienced skin reactions with it, switching to n-butyl-2-cyanoacrylate (Histoacryl) is unlikely to solve your problem since both agents cause allergic contact dermatitis at similar rates of 2-3%.

Key Differences Between the Two Adhesives

2-octyl cyanoacrylate (Dermabond) and n-butyl-2-cyanoacrylate (Histoacryl) are both tissue adhesives but differ in their chemical structure and physical properties:

  • Chain length: 2-octyl has a longer carbon chain (8 carbons) versus n-butyl (4 carbons), making octyl more flexible and stronger with better tensile strength
  • Application speed: N-butyl polymerizes faster and requires more rapid application technique
  • FDA approval: 2-octyl cyanoacrylate is FDA-approved for skin closure in the United States 1, while n-butyl is primarily used for endoscopic procedures (like variceal bleeding) 2
  • Closure time: N-butyl is significantly faster to apply (191 seconds vs 357 seconds for sutures) 3

The Skin Reaction Problem

Your concern about skin reactions is valid and switching adhesives won't help. The incidence of allergic contact dermatitis is essentially identical between the two agents:

  • 2-octyl cyanoacrylate: 2.7% incidence of ACD 4
  • N-butyl cyanoacrylate: 2.2% incidence of ACD 4
  • This difference is not statistically significant 4

Critical finding: In a large FDA MAUDE database review of 609 reported skin reactions to 2-octyl cyanoacrylate, the incidence ranged from 0.5% to 14% depending on the surgical population, with orthopedic procedures showing the highest rate (47% of reports) 5. The wide variation suggests patient-specific factors matter more than the adhesive type.

Clinical Implications for Your Practice

If patients had reactions to Dermabond (2-octyl cyanoacrylate), consider these alternatives instead:

  1. Subcuticular sutures: Provide equivalent cosmetic outcomes with lower dehiscence rates compared to tissue adhesives (RR 3.35 for dehiscence with adhesives vs sutures) 6

  2. Rapidly-absorbing synthetic sutures: Monofilament sutures cause less tissue reaction and don't require removal 7

  3. No suturing for appropriate wounds: For hemostatic first-degree lacerations, leaving wounds unsutured results in similar healing with less pain 7

Important Caveats

  • Cross-reactivity exists: 37% of cyanoacrylate-allergic patients are also allergic to methacrylates or acrylates 8, so avoid these materials in sensitive patients
  • Patch testing limitations: Standard ethyl cyanoacrylate patch testing only detects 29% of Dermabond-allergic patients; octyl cyanoacrylate 10% in petrolatum increases detection to 50% 8
  • Contact dermatitis from adhesives is well-documented in the dermatology literature 9, and isobornyl acrylate (a component in some adhesive formulations) can cause spreading allergic reactions

Bottom Line

Since both cyanoacrylate types cause reactions at similar rates, your best strategy is to avoid tissue adhesives entirely in patients with prior reactions and use traditional suturing techniques or leave appropriate wounds unsutured. The cosmetic outcomes are equivalent, and you'll eliminate the 2-3% risk of allergic contact dermatitis that occurs unpredictably without identifiable risk factors 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.